Drug Type Small molecule drug |
Synonyms KNP 503, KNP503 |
Target |
Mechanism SHP2 inhibitors(Src homology phosphotyrosyl phosphatase 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization KANAPH Therapeutics, Inc.Startup |
Active Organization KANAPH Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colorectal Cancer | Preclinical | KR | KANAPH Therapeutics, Inc.Startup | 05 Jul 2024 |
Glioblastoma | Preclinical | KR | KANAPH Therapeutics, Inc.Startup | 05 Jul 2024 |
Non-Small Cell Lung Cancer | Preclinical | KR | KANAPH Therapeutics, Inc.Startup | 05 Jul 2024 |